FilingsTodayNeopharm
At a glance
Neopharm filed 28 disclosures in the last 12 months, including 6 5% holder, 4 earnings and 1 insider. The most recent key filing was on Aug 7.
Revenue for 2025 was ₩132B, up 11.1% on 2024. Operating margin was 21.8% against 20.7% a year earlier. Debt was 11% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩79.8B and operating profit of ₩18.5B.
The 2025 annual report lists 192 employees with an average tenure of 4.9 years and average pay of ₩63.3M, #834 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩159M each on average. It paid ₩750 per common share in cash dividends, against ₩600 a year earlier (+25%). (주)잇츠한불 and related parties held 41.34% at year end.
From the 2025 annual report
Staff: 192 (91 men, 101 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩12.2B. Directors and auditors: 5, paid ₩794M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩750 | ₩600 | ₩750 |
| Payout ratio | 42.2% | 40.7% | 25.3% |
| Yield (as filed) | 3.90% | 4.90% | 3.00% |
| Total cash dividends | ₩11.7B | ₩9.4B | ₩5.9B |
Largest shareholder
(주)잇츠한불 holds 40.12%; with 4 related parties the group holds 41.34% of common shares at year end (from 40.35% at the start of the year).
Auditor: 대주회계법인 · opinion: Unqualified.
Rankings: Low debt #37 of 1,372 · Operating margin #48 of 1,376
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.